Scheduling, administration, biomarkers, and practical guidance.
10-20 days on / 10-14 days off. Morning dosing within 30 min of waking. Titrate from lower end; cycle is mandatory for receptor preservation.
10-20 days on / 10-14 days off. Titrate from lower end. Benzodiazepine co-use may alter Selank's non-sedative profile.
4-8 weeks on / 2-4 weeks off. Absolute contraindication in cancer history or active malignancy. Oncology baseline before initiation. Evidence base under data-integrity scrutiny.
4-6 weeks on / 2-4 weeks off. Subcutaneous is the characterised route; intranasal is supported in dosing tables. Oral viability is preclinical-supported but not clinically established.
Short half-life and mild activating profile via BDNF and dopaminergic modulation. Afternoon or evening dosing risks sleep-onset disruption; for split dosing keep second dose before 14:00.
Anxiolytic without sedation. Late-evening dosing may paradoxically increase alertness in some users via GABAergic modulation. Acute-stress dosing is event-onset-tied, not clock-time-tied.
Oral lipophilic absorption. Morning dosing aligns with natural neurotrophic activity windows. Empty stomach (30 min pre-food or 2 hours post-food) improves bioavailability.
BDNF-elevating profile aligns with waking neuroplasticity window. Mild activating effect makes morning the lower-risk default; later dosing has not been characterised for sleep impact.